#	Pagina
attuale pagina	/open-h2020/projects/206744/index.html
-1	/open-h2020/projects/220667/index.html
-2	/open-h2020/per-topic/396/list/index.html
-3	/open-h2020/projects/217892/results.html
-4	/open-h2020/projects/227241/index.html
-5	/open-h2020/projects/196193/index.html
-6	/open-h2020/projects/218717/index.html
-7	/open-h2020/per-topic/commerical/list/index.html
-8	/open-h2020/per-topic/chirality/list/index.html
-9	/open-h2020/projects/210065/index.html
-10	/open-h2020/projects/196582/index.html

Opendata, web and dolomites

OPTOGENERAPY SIGNED

Optogenetic Protein Therapy for Multiple Sclerosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Outcomes and
results

OPTOGENERAPY project word cloud

Explore the words cloud of the OPTOGENERAPY project. It provides you a very rough idea of what is the project "OPTOGENERAPY" about.

validate embedding standard optogenetic release scientist responds performance pull adherence immune efficiency therapies prevent stability clear chamber drug wireless sealed multiple smes optogenetics 30 combining proposes replacing implanted adverse ultrasion optogenerapy technological cellular listed device szlig polymeric demands penetration boston easily months prevents rejection barrier preclinically removed class cell micro optoelectronics cells validated meets intravenous miniaturization proof worldwide genexplain interferon ifn discontinuation implant losses enhanced 2014 optimal innovation confinement scientific neuromodulation light membrane peaks powered moulding encapsulate least huge overcoming autonomy active saving optical competitiveness competences push computer sclerosis neos engineering industrial plans engineered bio implantation big manufacturing biocompatibility magazine treatment biomaterials prototype subcutaneous revolutionize offers implants intensive acts minimal leader gene electronic porous time invasiveness science genetically subcutaneously safety synthetic market

Project "OPTOGENERAPY" data sheet

The following table provides information about the project.

Coordinator	FUNDACIO EURECAT Organization address address: AVENIDA UNIVERSITAT AUTONOMA 23 city: CERDANYOLA DEL VALLES (BARCELONA) postcode: 8290 website: www.eurecat.org/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Project website	http://www.optogenerapy.eu
Total cost	6˙233˙257 €
EC max contribution	4˙777˙257 € (77%)
Programme	1. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
Code Call	H2020-NMBP-2016-two-stage
Funding Scheme	RIA
Starting year	2017
Duration (year-month-day)	from 2017-01-01 to 2020-01-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	FUNDACIO EURECAT FUNDACIO EURECAT Organization address address: AVENIDA UNIVERSITAT AUTONOMA 23 city: CERDANYOLA DEL VALLES (BARCELONA) postcode: 8290 website: www.eurecat.org/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (CERDANYOLA DEL VALLES (BARCELONA))	coordinator	1˙256˙557.00
2	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	951˙345.00
3	BOSTON SCIENTIFIC LIMITED BOSTON SCIENTIFIC LIMITED Organization address address: BALLYBRIT BUSINESS PARK city: GALWAY postcode: H91 website: www.bostonscientific.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (GALWAY)	participant	805˙880.00
4	GENEXPLAIN GMBH GENEXPLAIN GMBH Organization address address: AM EXER 19 B city: WOLFENBUTTEL postcode: 38302 website: www.genexplain.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (WOLFENBUTTEL)	participant	386˙100.00
5	ERASMUS UNIVERSITEIT ROTTERDAM ERASMUS UNIVERSITEIT ROTTERDAM Organization address address: BURGEMEESTER OUDLAAN 50 city: ROTTERDAM postcode: 3062 PA website: www.eur.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (ROTTERDAM)	participant	322˙590.00
6	NEOS SURGERY SL NEOS SURGERY SL Organization address address: PASEO MIKELETEGI - PARQUE TECNOLOGICO MIRAMON 2 city: DONOSTIA SAN SEBASTIAN postcode: 20009 website: www.neosurgery.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (DONOSTIA SAN SEBASTIAN)	participant	303˙375.00
7	POLITECHNIKA LODZKA POLITECHNIKA LODZKA Organization address address: ULICA ZEROMSKIEGO 116 city: LODZ postcode: 90 924 website: www.p.lodz.pl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	PL (LODZ)	participant	255˙000.00
8	TWOPTICS SYSTEMS DESIGN SL TWOPTICS SYSTEMS DESIGN SL Organization address address: CALLE JORDI GIRONA 1-3 PARC UPC EDIFICIO K2M OFF 316 CAMPUS NORD city: BARCELONA postcode: 8034 website: www.twoptics.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	participant	246˙410.00
9	ULTRASION S.L. ULTRASION S.L. Organization address address: AV. UNIVERSITAT AUTONOMA 23 city: CERDANYOLA DEL VALLES postcode: 8290 website: www.ultrasion.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (CERDANYOLA DEL VALLES)	participant	172˙500.00
10	ASOCIACION ESPANOLA DE NORMALIZACION ASOCIACION ESPANOLA DE NORMALIZACION Organization address address: CALLE GENOVA 6 city: MADRID postcode: 28004 website: www.aenor.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (MADRID)	participant	77˙500.00
11	EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH Organization address address: Raemistrasse 101 city: ZUERICH postcode: 8092 website: https://www.ethz.ch/de.html contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (ZUERICH)	participant	0.00

Map

Project objective

Optogenerapy proposes a new interferon-ß (IFN-ß) drug delivery system to revolutionize Multiple Sclerosis treatment.

The aim is to develop and validate a new bio-electronic cell based implant device to be implanted subcutaneously providing controlled drug release during at least 6 months. The cell confinement within a chamber sealed by a porous membrane allows the device to be easily implanted or removed. At the same time, this membrane acts to prevent immune rejection and offers long-term safety in drug release while overcoming the adverse effects of current cellular therapies. Wireless powered optogenetics – light controlling the cellular response of genetically engineered cells – is used to control the production of IFN-ß.

Replacing standard intravenous IFN-ß delivery by subcutaneous delivery prevents short and long term side effects and efficiency-losses related to drug peaks and discontinuation, while saving non-adherence costs.

It is a low-cost system enabling large scale manufacturing and reduction of time to market up to 30% compared to other cell therapies, combining: - Polymeric biomaterials with strong optical, biocompatibility and barrier requirements, to build the cell chamber and to encapsulate the optoelectronics. - Optoelectronics miniaturization, autonomy and optical performance. - Optimal cellular engineering design, enhanced by computer modelling, for stability and performance of the synthetic optogenetic gene pathway over long-term implantation. - Micro moulding enabling optoelectronics and membrane embedding for safety and minimal invasiveness.

The innovation potential is so huge that a proof-of-concept was listed by Scientist Magazine as one of the 2014’s big advances in science.

In our top-class consortium, industrial pull meets technological push, ensuring that the preclinically validated prototype obtained at the end responds to market demands.

BOSTON SCIENTIFIC, worldwide leader in neuromodulation active implants, has clear exploitation plans and high market penetration potential. 4 research intensive SMEs: TWO, GENEXPLAIN, NEOS and ULTRASION bring specific competences while increasing their own competitiveness.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OPTOGENERAPY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OPTOGENERAPY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.3.)

SYNAMERA (2015)

Synergies in Nanotechnologies, Materials and Production in the European Research Area

Read More

SMARTFAN (2018)

Smart by Design and Intelligent by Architecture for turbine blade fan and structural components systems

Read More

CORNET (2018)

Multiscale modelling and characterization to optimize the manufacturing processes of Organic Electronics materials and devices

Read More